Lorbrena — Competitive Intelligence Brief

Lorbrena (lorlatinib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase Inhibitor [EPC]. Area: Oncology.

marketed Kinase Inhibitor [EPC] ALK tyrosine kinase receptor Oncology

Target snapshot

Lorbrena (lorlatinib) — Pfizer. Lorbrena works by blocking the activity of the ALK tyrosine kinase receptor, which is a protein that helps cancer cells grow.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lorbrena TARGET	lorlatinib	Pfizer	marketed	Kinase Inhibitor [EPC]	ALK tyrosine kinase receptor	2018-01-01
Lorbrena	Lorlatinib	Pfizer	marketed	Kinase Inhibitor [EPC]	ALK tyrosine kinase receptor	2018-01-01
Alunbrig	brigatinib	Takeda	marketed	Kinase Inhibitor [EPC]	ALK tyrosine kinase receptor	2017-01-01
Tagrisso	osimertinib	AstraZeneca	marketed	Kinase Inhibitor [EPC]	ALK tyrosine kinase receptor	2015-01-01
Alecensa	alectinib	Hoffmann-La Roche	marketed	Kinase Inhibitor	ALK tyrosine kinase receptor	2015-01-01
Zykadia	ceritinib	Novartis	marketed	Kinase Inhibitor [EPC]	ALK tyrosine kinase receptor	2014-01-01
Wayrilz	RILZABRUTINIB	Genzyme Corp	marketed	Kinase Inhibitor [EPC]		2025-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2032-07-25 — Tagrisso · 9732058 · US
• 2032-07-25 — Tagrisso · 11524951 · US
• 2032-08-08 — Tagrisso · 8946235 · US
• 2035-01-02 — Tagrisso · 10183020 · US

Sponsor landscape (Kinase Inhibitor [EPC] class)

1. · 12 drugs in this class
2. Pfizer · 7 drugs in this class
3. Novartis · 3 drugs in this class
4. Bayer · 2 drugs in this class
5. Boehringer Ingelheim · 2 drugs in this class
6. AstraZeneca · 2 drugs in this class
7. Beigene Usa Inc · 1 drug in this class
8. BeiGene · 1 drug in this class
9. AbbVie · 1 drug in this class
10. Bristol · 1 drug in this class